Log in to #JTCVS to read the mortality risks, survival times, and regional differences after coronary artery bypass grafting or percutaneous coronary intervention in patients with diabetes and multivessel disease in a large nationwide cohort of patients: https://t.co/PGf8Pz6Nhn
🚨2025 @EACTS and @ESC_Journals guidelines have been released. Great job by those involved. As all non evidences based recommendations, most are subject to different perspectives. The authors of current guidelines have jeopardized the future of pts who need a second procedure…
MATTERHORN trial. TEER vs Surgery. A trial which aims to evaluate is TEER is better than surgery when we still do not know if it is better than medical treatment. These are my comments…https://t.co/jD587bccxK. @drjohnm@rafasadaba@pomyers@EduQuintanaCVS @michaelTCTMD
Brutal statement from @EACTS@escardio has just made history. For the first time, PCI has been downgraded as recommendation in patients with LM disease. This thoughtful decision was made after careful analysis of evidence. Here are the main key points…
Prosthetic valve endocarditis after TAVR / SAVR
5% of patients
96,2% 5 years mortality
"Once you have endocarditis, you're almost destined to die,"
https://t.co/R48NsmpKzd vía @medscape
In patients requiring replacement of the aortic valve and ascending aorta, risk of enlargement of the remaining aortic root over time is minimal, negating the need for prophylactic root replacement. #JTCVS https://t.co/rvUzmId6Wm #tssmn
Fate of the Aortic Arch Following Surgery on Aortic Root and Ascending Aorta in Bicuspid Aortic Valve https://t.co/pBWjmypqeR #cardiology#bentall#aneurysm#bicuspid
Continually accumulating evidence: #CABG tops #PCI for those with diabetes, heart disease and left ventricular dysfunction. https://t.co/MySYnGWSpz #ctsurgery#cardiology